Vigil Neuroscience, Inc.
VIGLHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | −$89.7M | −$88.9M | −$68.9M | −$42.4M |
| Net income | −$84.3M | −$82.6M | −$68.3M | −$43.3M |
| Total assets | $117.7M | $140.9M | $200.4M | $102.4M |
| Total liabilities | $46.1M | $24.6M | $11.3M | $9.9M |
| Equity | $71.6M | $116.3M | $189.1M | −$69.4M |
| EPS (diluted) | $-2.07 | $-2.13 | $-2.16 | $-28.26 |
| Shares out. | 36.9M | 35.6M | 35.6M | 1.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −117.6%
- Return on assets
- −71.6%
- Return on capital (ROCE)
- −107.3%
- Liabilities / assets
- 39.1%
- Debt / equity
- 0.64×
- Book value / share
- $1.94
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -8.29distress
- Accruals / assets
- −28.1%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Beryl Capital Management LlcPassive (13G)Nov 14, 2025
- Glazer Capital, LlcPassive (13G)Aug 14, 2025
- Biotechnology Value Fund L PPassive (13G)Aug 14, 2025
- Atlas Venture Fund Xii, L.P.Activist (13D)Aug 7, 2025
- Vida Ventures Gp Iii, L.L.C.Activist (13D)Jun 12, 2025
- Northpond Ventures, LpActivist (13D)May 27, 2025
- Invus Global Management, LlcPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Atlas Venture Fund Xii, L.P.10% owner | Aug 5, 2025 | D | 4.8M | — |
| Thistle MaryDirector | Aug 5, 2025 | D | 5,000 | — |
| Budd Haeberlein Samantha L.Director | Aug 5, 2025 | D | 5,000 | — |
| Ziolkowski Jennifer LynnOfficer — Chief Financial Officer | Aug 5, 2025 | D | 4,000 | — |
| Booth BruceDirector | Aug 5, 2025 | D | 5,000 | — |
| Vitorovic StefanDirector | Aug 5, 2025 | D | 5,000 | — |
| Magovcevic-Liebisch IvanaOfficer — President and CEO | Aug 5, 2025 | D | 222,687 | — |
| Bruhn Suzanne LouiseDirector | Aug 5, 2025 | D | 5,000 | — |
| Blanchard Cheryl RDirector | Aug 5, 2025 | D | 5,000 | — |
| Koenig GerhardDirector | Aug 5, 2025 | D | 5,000 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jul 31, 2025 | 567,651 | 1.0 | +26.9% |
| Jul 15, 2025 | 447,390 | 1.0 | +19.2% |
| Jun 30, 2025 | 375,443 | 1.0 | +19.1% |
| Jun 13, 2025 | 315,309 | 1.0 | -14.2% |
| May 30, 2025 | 367,481 | 1.0 | -9.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder vote · Other material eventAug 5, 2025
- Other material eventJul 28, 2025
- Other material eventJul 17, 2025
- Shareholder voteMay 23, 2025
- Entered a material agreement · Regulation FD disclosureMay 22, 2025
- Results of operationsMay 7, 2025
- Results of operationsMar 13, 2025
- Regulation FD disclosure · Other material eventJan 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/ANov 14, 2025
- 15-12GAug 15, 2025
- SCHEDULE 13G/AAug 14, 2025
- SCHEDULE 13G/AAug 14, 2025
- EFFECTAug 7, 2025
- EFFECTAug 7, 2025
- SCHEDULE 13D/AAug 7, 2025
- 4Aug 7, 2025
- S-8 POSAug 5, 2025
- S-8 POSAug 5, 2025
- S-8 POSAug 5, 2025
- S-8 POSAug 5, 2025
- POS AMAug 5, 2025
- POS AMAug 5, 2025
- 4Aug 5, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.